Scott Allen Armstrong - Publications

Affiliations: 
Biology, Molecular and Cellular Harvard University, Cambridge, MA, United States 
Area:
General Biology, Molecular Biology, Biochemistry, Oncology
Website:
https://hsci.harvard.edu/people/scott-armstrong-md-phd

146 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Barbosa K, Deshpande A, Chen BR, Ghosh A, Sun Y, Dutta S, Weetall M, Dixon J, Armstrong SA, Bohlander SK, Deshpande AJ. Acute Myeloid Leukemia Driven by the CALM-AF10 Fusion Gene is Dependent on BMI1. Experimental Hematology. PMID 31022428 DOI: 10.1016/j.exphem.2019.04.003  1
2018 Park SM, Cho H, Thornton AM, Barlowe TS, Chou T, Chhangawala S, Fairchild L, Taggart J, Chow A, Schurer A, Gruet A, Witkin MD, Kim JH, Shevach EM, Krivtsov A, ... Armstrong SA, et al. IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. Cell Stem Cell. PMID 30472158 DOI: 10.1016/j.stem.2018.10.016  1
2018 Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, ... ... Armstrong SA, et al. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 7. PMID 30431433 DOI: 10.7554/eLife.41305  1
2018 Chu SH, Song EJ, Chabon JR, Minehart J, Matovina CN, Makofske JL, Frank ES, Ross K, Koche RP, Feng Z, Xu H, Krivtsov A, Nussenzweig A, Armstrong SA. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by and activated . Blood Advances. 2: 2478-2490. PMID 30266823 DOI: 10.1182/bloodadvances.2018021592  1
2018 Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR, Waters NJ, Suttle AB, Clawson A, Pollock R, ... ... Armstrong SA, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. PMID 29724899 DOI: 10.1182/blood-2017-12-818948  1
2018 Hoshii T, Cifani P, Feng Z, Huang CH, Koche R, Chen CW, Delaney CD, Lowe SW, Kentsis A, Armstrong SA. A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response. Cell. 172: 1007-1021.e17. PMID 29474905 DOI: 10.1016/j.cell.2018.01.032  1
2018 Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY, ... ... Armstrong SA, et al. LSD1 inhibition exerts its anti-leukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood. PMID 29453291 DOI: 10.1182/blood-2017-09-807024  1
2018 Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, ... ... Armstrong SA, et al. MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia. Cancer Discovery. PMID 29431698 DOI: 10.1158/2159-8290.CD-17-1271  0.01
2018 Ramaswamy K, Forbes L, Minuesa G, Gindin T, Brown F, Kharas MG, Krivtsov AV, Armstrong SA, Still E, de Stanchina E, Knoechel B, Koche R, Kentsis A. Peptidomimetic blockade of MYB in acute myeloid leukemia. Nature Communications. 9: 110. PMID 29317678 DOI: 10.1038/s41467-017-02618-6  1
2017 Mar BG, Chu SH, Kahn JD, Krivstov AV, Koche R, Castellano CA, Kotlier JL, Zon RL, McConkey ME, Chabon J, Chappell R, Grauman PV, Hsieh JJ, Armstrong SA, Ebert BL. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood. PMID 29018079 DOI: 10.1182/blood-2017-03-775569  1
2017 Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur IC, Rodríguez-Fos E, Gonzalez S, Puiggròs M, Blackford AN, Mason CE, de Stanchina E, Gönen M, ... ... Armstrong SA, et al. Erratum: PGBD5 promotes site-specific oncogenic mutations in human tumors. Nature Genetics. 49: 1558. PMID 28951624 DOI: 10.1038/ng1017-1558b  1
2017 Wang SP, Tang Z, Chen CW, Shimada M, Koche RP, Wang LH, Nakadai T, Chramiec A, Krivtsov AV, Armstrong SA, Roeder RG. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. Molecular Cell. 67: 308-321.e6. PMID 28732206 DOI: 10.1016/j.molcel.2017.06.028  1
2017 Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur IC, Rodríguez-Fos E, Gonzalez S, Puiggròs M, Blackford AN, Mason CE, de Stanchina E, Gönen M, ... ... Armstrong SA, et al. PGBD5 promotes site-specific oncogenic mutations in human tumors. Nature Genetics. PMID 28504702 DOI: 10.1038/ng.3866  1
2017 Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, Calvo-Vidal MN, Chou T, Chow A, Minuesa G, Park SM, Barlowe TS, Taggart J, Tivnan P, Deering RP, Chu LP, ... ... Armstrong SA, et al. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature Genetics. PMID 28436985 DOI: 10.1038/ng.3854  1
2017 Krivtsov AV, Hoshii T, Armstrong SA. Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia. Cold Spring Harbor Perspectives in Medicine. PMID 28242784 DOI: 10.1101/cshperspect.a026658  1
2017 Wan L, Wen H, Li Y, Lyu J, Xi Y, Hoshii T, Joseph JK, Wang X, Loh YE, Erb MA, Souza AL, Bradner JE, Shen L, Li W, Li H, ... ... Armstrong SA, et al. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature. PMID 28241141 DOI: 10.1038/nature21687  1
2017 Valerio DG, Xu H, Chen CW, Hoshii T, Eisold ME, Delaney C, Cusan M, Deshpande AJ, Huang CH, Lujambio A, Zheng YG, Zuber J, Pandita TK, Lowe SW, Armstrong SA. Histone acetyltransferase activity of MOF is required for MLL-AF9 leukemogenesis. Cancer Research. PMID 28202522 DOI: 10.1158/0008-5472.CAN-16-2374  1
2016 Xu H, Valerio DG, Eisold ME, Sinha A, Koche RP, Hu W, Chen CW, Chu SH, Brien GL, Park CY, Hsieh JJ, Ernst P, Armstrong SA. NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. Cancer Cell. PMID 27889185 DOI: 10.1016/j.ccell.2016.10.019  1
2016 Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, ... ... Armstrong SA, et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine. PMID 27841873 DOI: 10.1038/nm.4210  1
2016 Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C. Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus. Blood. PMID 27827825 DOI: 10.1182/blood-2016-04-706978  1
2016 Morgado-Palacin I, Day A, Murga M, Lafarga V, Anton ME, Tubbs A, Chen HT, Ergan A, Anderson R, Bhandoola A, Pike KG, Barlaam B, Cadogan E, Wang X, Pierce AJ, ... ... Armstrong SA, et al. Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML. Science Signaling. 9: ra91. PMID 27625305 DOI: 10.1126/scisignal.aad8243  1
2016 Kühn MW, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, Cusan M, Farnoud N, Mupo A, Grove C, Koche R, Bradner JE, de Stanchina E, Vassiliou GS, Hoshii T, ... Armstrong SA, et al. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discovery. PMID 27535106 DOI: 10.1158/2159-8290.CD-16-0237  1
2016 Henssen AG, Jiang E, Zhuang J, Pinello L, Socci ND, Koche R, Gonen M, Villasante CM, Armstrong SA, Bauer DE, Weng Z, Kentsis A. Forward genetic screen of human transposase genomic rearrangements. Bmc Genomics. 17: 548. PMID 27491780 DOI: 10.1186/s12864-016-2877-x  1
2016 Wang K, Sanchez-Martin M, Wang X, Knapp KM, Koche R, Vu L, Nahas MK, He J, Hadler M, Stein EM, Tallman MS, Donahue AL, Frampton GM, Lipson D, Roels S, ... ... Armstrong SA, et al. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia. PMID 27363283 DOI: 10.1038/leu.2016.166  1
2016 Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, ... ... Armstrong SA, et al. Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature Medicine. 22: 692. PMID 27270779 DOI: 10.1038/nm0616-692d  1
2016 LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, ... ... Armstrong SA, et al. Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature Medicine. 22: 578-579. PMID 27270773 DOI: 10.1038/nm.4094  1
2016 Wang X, Chen CW, Armstrong SA. The role of DOT1L in the maintenance of leukemia gene expression. Current Opinion in Genetics & Development. 36: 68-72. PMID 27151433 DOI: 10.1016/j.gde.2016.03.015  1
2016 Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, ... ... Armstrong SA, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nature Medicine. PMID 27135740 DOI: 10.1038/nm.4097  1
2016 Brien GL, Valerio DG, Armstrong SA. Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell. 29: 464-76. PMID 27070701 DOI: 10.1016/j.ccell.2016.03.007  1
2016 Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. The Journal of Clinical Investigation. PMID 26927674 DOI: 10.1172/JCI80825  1
2016 Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna JN, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, Bernt KM, Neff T. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia. Cell Reports. PMID 26904942 DOI: 10.1016/j.celrep.2016.01.064  1
2016 Zhu N, Chen M, Eng R, DeJong J, Sinha AU, Rahnamay NF, Koche R, Al-Shahrour F, Minehart JC, Chen CW, Deshpande AJ, Xu H, Chu SH, Ebert BL, Roeder RG, ... Armstrong SA, et al. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. The Journal of Clinical Investigation. PMID 26878175 DOI: 10.1172/JCI82978  1
2015 Armstrong SA, Rape M. Editorial overview: Differentiation and disease. Current Opinion in Cell Biology. PMID 26626586 DOI: 10.1016/j.ceb.2015.11.001  1
2015 Cai SF, Chen CW, Armstrong SA. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Molecular Cell. 60: 561-70. PMID 26590715 DOI: 10.1016/j.molcel.2015.10.042  1
2015 Chen M, Zhu N, Liu X, Laurent B, Tang Z, Eng R, Shi Y, Armstrong SA, Roeder RG. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes & Development. 29: 2123-39. PMID 26494788 DOI: 10.1101/gad.267278.115  1
2015 Brien GL, Healy E, Jerman E, Conway E, Fadda E, O'Donovan D, Krivtsov AV, Rice AM, Kearney CJ, Flaus A, McDade SS, Martin SJ, McLysaght A, O'Connell DJ, Armstrong SA, et al. A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence. Genes & Development. PMID 26494712 DOI: 10.1101/gad.267930.115  1
2015 Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia. PMID 26487272 DOI: 10.1038/leu.2015.292  1
2015 Chen S, Yang Z, Wilkinson AW, Deshpande AJ, Sidoli S, Krajewski K, Strahl BD, Garcia BA, Armstrong SA, Patel DJ, Gozani O. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79. Molecular Cell. PMID 26439302 DOI: 10.1016/j.molcel.2015.08.019  1
2015 LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, ... ... Armstrong SA, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nature Medicine. PMID 26437366 DOI: 10.1038/nm.3947  1
2015 Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, Caruso BT, Arefolov A, Fadeyi O, Christie AL, Du K, Banka D, Schneider EV, Jestel A, Zou G, ... ... Armstrong SA, et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 526: 273-6. PMID 26416749 DOI: 10.1038/nature14904  1
2015 Ye M, Zhang H, Yang H, Koche R, Staber PB, Cusan M, Levantini E, Welner RS, Bach CS, Zhang J, Krivtsov AV, Armstrong SA, Tenen DG. Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. Cell Stem Cell. PMID 26412561 DOI: 10.1016/j.stem.2015.08.011  1
2015 Chen CW, Armstrong SA. Targeting DOT1L and HOX Gene Expression in MLL-Rearranged Leukemia and Beyond. Experimental Hematology. PMID 26118503 DOI: 10.1016/j.exphem.2015.05.012  1
2015 Danis E, Yamauchi T, Echanique K, Haladyna J, Kalkur R, Riedel S, Zhu N, Xie H, Bernt KM, Orkin SH, Armstrong SA, Neff T. Inactivation of Eed Impedes MLL-AF9 Mediated Leukemogenesis Through Cdkn2a-Dependent and Cdkn2a-Independent Mechanisms in a Murine Model. Experimental Hematology. PMID 26118502 DOI: 10.1016/j.exphem.2015.06.005  1
2015 Kühn MW, Armstrong SA. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia. Cancer Cell. 27: 431-3. PMID 25873167 DOI: 10.1016/j.ccell.2015.03.012  1
2015 Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, ... ... Armstrong SA, et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nature Medicine. 21: 335-43. PMID 25822366 DOI: 10.1038/nm.3832  1
2015 Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SA. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2348-58. PMID 25688158 DOI: 10.1158/1078-0432.CCR-14-1290  1
2015 Kühn MW, Hadler MJ, Daigle SR, Koche RP, Krivtsov AV, Olhava EJ, Caligiuri MA, Huang G, Bradner JE, Pollock RM, Armstrong SA. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica. 100: e190-3. PMID 25596271 DOI: 10.3324/haematol.2014.115337  1
2015 Heidel FH, Arreba-Tutusaus P, Armstrong SA, Fischer T. Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia's genetic diversity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 240-8. PMID 25593343 DOI: 10.1158/1078-0432.CCR-14-1436  1
2015 Yi JS, Federation AJ, Qi J, Dhe-Paganon S, Hadler M, Xu X, St Pierre R, Varca AC, Wu L, Marineau JJ, Smith WB, Souza A, Chory EJ, Armstrong SA, Bradner JE. Structure-guided DOT1L probe optimization by label-free ligand displacement. Acs Chemical Biology. 10: 667-74. PMID 25397901 DOI: 10.1021/cb500796d  1
2014 Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, East-Seletsky A, Ali LD, Gerath WF, Pantel SE, Lizotte PH, Jiang G, Hsiao J, Tsherniak A, Dwinell E, ... ... Armstrong SA, et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Scientific Data. 1: 140035. PMID 25984343 DOI: 10.1038/sdata.2014.35  1
2014 Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, Chiosis G, Chung YR, Pandey S, van den Brink MR, Armstrong SA, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 111: E5401-10. PMID 25516983 DOI: 10.1073/pnas.1407792111  1
2014 Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, et al. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell. 15: 775-90. PMID 25479751 DOI: 10.1016/j.stem.2014.11.010  1
2014 Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, ... ... Armstrong SA, et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 26: 896-908. PMID 25464900 DOI: 10.1016/j.ccell.2014.10.009  1
2014 Lee D, Sykes SM, Kalaitzidis D, Lane AA, Kfoury Y, Raaijmakers MH, Wang YH, Armstrong SA, Scadden DT. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports. 3: 832-40. PMID 25418727 DOI: 10.1016/j.stemcr.2014.08.011  1
2014 Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes & Development. 28: 1800-14. PMID 25128497 DOI: 10.1101/gad.244368.114  1
2014 Santos MA, Faryabi RB, Ergen AV, Day AM, Malhowski A, Canela A, Onozawa M, Lee JE, Callen E, Gutierrez-Martinez P, Chen HT, Wong N, Finkel N, Deshpande A, Sharrow S, ... ... Armstrong SA, et al. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature. 514: 107-11. PMID 25079327 DOI: 10.1038/nature13483  1
2014 Hanoun M, Zhang D, Mizoguchi T, Pinho S, Pierce H, Kunisaki Y, Lacombe J, Armstrong SA, Dührsen U, Frenette PS. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell. 15: 365-75. PMID 25017722 DOI: 10.1016/j.stem.2014.06.020  1
2014 Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 124: 13-23. PMID 24764564 DOI: 10.1182/blood-2014-02-558114  1
2014 Koche RP, Armstrong SA. Genomic dark matter sheds light on EVI1-driven leukemia. Cancer Cell. 25: 407-8. PMID 24735919 DOI: 10.1016/j.ccr.2014.03.031  1
2014 Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, Neuberg DS, Sinha AU, Sallan SE, Silverman LB, Kung AL, Lo Nigro L, Ebert BL, Armstrong SA. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nature Communications. 5: 3469. PMID 24662245 DOI: 10.1038/ncomms4469  1
2014 Wee S, Dhanak D, Li H, Armstrong SA, Copeland RA, Sims R, Baylin SB, Liu XS, Schweizer L. Targeting epigenetic regulators for cancer therapy. Annals of the New York Academy of Sciences. 1309: 30-6. PMID 24571255 DOI: 10.1111/nyas.12356  1
2014 Ng CE, Sinha A, Krivtsov A, Dias S, Chang J, Armstrong SA, Kalaitzidis D. KRas(G12D)-evoked leukemogenesis does not require β-catenin. Leukemia. 28: 698-702. PMID 24189294 DOI: 10.1038/leu.2013.328  1
2013 Chu SH, Armstrong SA. Stem cells: Dual response to Ras mutation. Nature. 504: 91-2. PMID 24284623 DOI: 10.1038/nature12840  1
2013 Altschuler GM, Hofmann O, Kalatskaya I, Payne R, Ho Sui SJ, Saxena U, Krivtsov AV, Armstrong SA, Cai T, Stein L, Hide WA. Pathprinting: An integrative approach to understand the functional basis of disease. Genome Medicine. 5: 68. PMID 23890051 DOI: 10.1186/gm472  1
2013 Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, ... ... Armstrong SA, et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 24: 45-58. PMID 23770013 DOI: 10.1016/j.ccr.2013.05.004  1
2013 Neff T, Armstrong SA. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood. 121: 4847-53. PMID 23649466 DOI: 10.1182/blood-2013-02-474833  1
2013 Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 121: 3692-702. PMID 23487027 DOI: 10.1182/blood-2012-05-432989  1
2013 Ho LL, Sinha A, Verzi M, Bernt KM, Armstrong SA, Shivdasani RA. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Molecular and Cellular Biology. 33: 1735-45. PMID 23428873 DOI: 10.1128/MCB.01463-12  1
2013 Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 121: 2533-41. PMID 23361907 DOI: 10.1182/blood-2012-11-465120  1
2013 Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, Ibrahim S, Skokos D, Armstrong SA, Levine RL, Park CY, et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. The Journal of Experimental Medicine. 210: 301-19. PMID 23359070 DOI: 10.1084/jem.20121484  1
2013 Heidel FH, Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Döhner K, Vasioukhin V, Fischer T, Armstrong SA. The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML Journal of Experimental Medicine. 210: 15-22. PMID 23277453 DOI: 10.1084/jem.20120596  1
2013 Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJM, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML Leukemia. 27: 852-860. PMID 23235717 DOI: 10.1038/leu.2012.363  1
2013 Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 27: 813-22. PMID 23138183 DOI: 10.1038/leu.2012.327  1
2012 Krivtsov AV, Armstrong SA. Cancer. Can one cell influence cancer heterogeneity? Science (New York, N.Y.). 338: 1035-6. PMID 23180850 DOI: 10.1126/science.1231594  1
2012 Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 11: 429-39. PMID 22958934 DOI: 10.1016/j.stem.2012.06.009  1
2012 Deshpande AJ, Bradner J, Armstrong SA. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends in Immunology. 33: 563-70. PMID 22867873 DOI: 10.1016/j.it.2012.06.002  1
2012 Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 119: 5838-49. PMID 22553314 DOI: 10.1182/blood-2011-11-393827  1
2012 Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW, Armstrong SA. Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 10: 412-24. PMID 22482506 DOI: 10.1016/j.stem.2012.02.017  1
2012 Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proceedings of the National Academy of Sciences of the United States of America. 109: 5028-33. PMID 22396593 DOI: 10.1073/pnas.1202258109  1
2012 Sinha AU, Armstrong SA. iCanPlot: visual exploration of high-throughput omics data using interactive Canvas plotting. Plos One. 7: e31690. PMID 22393367 DOI: 10.1371/journal.pone.0031690  1
2012 Onder TT, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, Cahan P, Marcarci BO, Unternaehrer J, Gupta PB, Lander ES, Armstrong SA, Daley GQ. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 483: 598-602. PMID 22388813 DOI: 10.1038/nature10953  1
2012 Mar BG, Bullinger L, Basu E, Schlis K, Silverman LB, Döhner K, Armstrong SA. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia Leukemia. 26: 1881-1883. PMID 22377896 DOI: 10.1038/leu.2012.56  1
2012 Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes & Development. 26: 344-9. PMID 22345515 DOI: 10.1101/gad.184341.111  1
2012 Ho Sui SJ, Begley K, Reilly D, Chapman B, McGovern R, Rocca-Sera P, Maguire E, Altschuler GM, Hansen TA, Sompallae R, Krivtsov A, Shivdasani RA, Armstrong SA, Culhane AC, Correll M, et al. The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Research. 40: D984-91. PMID 22121217 DOI: 10.1093/nar/gkr1051  1
2011 Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2011: 354-60. PMID 22160057 DOI: 10.1182/asheducation-2011.1.354  1
2011 Bernt KM, Armstrong SA. A role for DOT1L in MLL-rearranged leukemias. Epigenomics. 3: 667-70. PMID 22126283 DOI: 10.2217/epi.11.98  1
2011 Sinha AU, Merrill E, Armstrong SA, Clark TW, Das S. eXframe: reusable framework for storage, analysis and visualization of genomics experiments. Bmc Bioinformatics. 12: 452. PMID 22103807 DOI: 10.1186/1471-2105-12-452  1
2011 Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Schöll C, Tothova Z, Attar EC, ... ... Armstrong SA, et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 146: 697-708. PMID 21884932 DOI: 10.1016/j.cell.2011.07.032  1
2011 Heidel FH, Mar BG, Armstrong SA. Self-renewal related signaling in myeloid leukemia stem cells. International Journal of Hematology. 94: 109-17. PMID 21800073 DOI: 10.1007/s12185-011-0901-0  1
2011 Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland DG, Scadden DT, Armstrong SA, Williams DA. Differential niche and Wnt requirements during acute myeloid leukemia progression Blood. 118: 2849-2856. PMID 21765021 DOI: 10.1182/blood-2011-03-345165  1
2011 Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 20: 66-78. PMID 21741597 DOI: 10.1016/j.ccr.2011.06.010  1
2011 Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, ... ... Armstrong SA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 20: 53-65. PMID 21741596 DOI: 10.1016/j.ccr.2011.06.009  1
2011 Deshpande AJ, Rouhi A, Lin Y, Stadler C, Greif PA, Arseni N, Opatz S, Quintanilla-Fend L, Holzmann K, Hiddemann W, Döhner K, Döhner H, Xu G, Armstrong SA, Bohlander SK, et al. The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia. 25: 1718-27. PMID 21681188 DOI: 10.1038/leu.2011.153  1
2011 Kalaitzidis D, Armstrong SA. Cancer: The flipside of Notch. Nature. 473: 159-60. PMID 21562551 DOI: 10.1038/473159a  1
2011 Zimmer SN, Zhou Q, Zhou T, Cheng Z, Abboud-Werner SL, Horn D, Lecocke M, White R, Krivtsov AV, Armstrong SA, Kung AL, Livingston DM, Rebel VI. Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. Blood. 118: 69-79. PMID 21555743 DOI: 10.1182/blood-2010-09-307942  1
2011 Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH, De Silva I, Valk PJ, Delwel R, Armstrong SA, Döhner H, et al. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Research. 71: 4117-29. PMID 21505102 DOI: 10.1158/0008-5472.CAN-11-0176  1
2010 Shannon K, Armstrong SA. Genetics, epigenetics, and leukemia. The New England Journal of Medicine. 363: 2460-1. PMID 21067376 DOI: 10.1056/NEJMe1012071  1
2010 Claus R, Plass C, Armstrong SA, Bullinger L. DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncology (London, England). 6: 1415-31. PMID 20919827 DOI: 10.2217/fon.10.110  1
2010 Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (New York, N.Y.). 327: 1650-3. PMID 20339075 DOI: 10.1126/science.1186624  1
2010 Juszczynski P, Rodig SJ, Ouyang J, O'Donnell E, Takeyama K, Mlynarski W, Mycko K, Szczepanski T, Gaworczyk A, Krivtsov A, Faber J, Sinha AU, Rabinovich GA, Armstrong SA, Kutok JL, et al. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2122-30. PMID 20332322 DOI: 10.1158/1078-0432.CCR-09-2765  1
2010 Kotani A, Ha D, Schotte D, den Boer ML, Armstrong SA, Lodish HF. A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle (Georgetown, Tex.). 9: 1037-42. PMID 20237425  1
2010 Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 709-28. PMID 20227509 DOI: 10.1016/j.bbmt.2010.03.002  1
2010 Bullinger L, Armstrong SA. HELP for AML: Methylation Profiling Opens New Avenues Cancer Cell. 17: 1-3. PMID 20129241 DOI: 10.1016/j.ccr.2009.12.033  1
2010 Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJ, Armstrong SA, Pieters R. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood. 115: 1018-25. PMID 19965632 DOI: 10.1182/blood-2009-02-205963  1
2009 Krivtsov AV, Feng Z, Armstrong SA. Transformation from committed progenitor to leukemia stem cells. Annals of the New York Academy of Sciences. 1176: 144-9. PMID 19796242 DOI: 10.1111/j.1749-6632.2009.04966.x  1
2009 Kotani A, Ha D, Hsieh J, Rao PK, Schotte D, den Boer ML, Armstrong SA, Lodish HF. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood. 114: 4169-78. PMID 19749093 DOI: 10.1182/blood-2008-12-191619  1
2009 Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell. 4: 559-67. PMID 19497284 DOI: 10.1016/j.stem.2009.03.016  1
2009 Neff T, Armstrong SA. Chromatin maps, histone modifications and leukemia. Leukemia. 23: 1243-51. PMID 19322211 DOI: 10.1038/leu.2009.40  1
2009 Krivtsov AV, Wang Y, Feng Z, Armstrong SA. Gene expression profiling of leukemia stem cells. Methods in Molecular Biology (Clifton, N.J.). 538: 231-46. PMID 19277590 DOI: 10.1007/978-1-59745-418-6_11  1
2009 Bernt KM, Armstrong SA. Leukemia stem cells and human acute lymphoblastic leukemia. Seminars in Hematology. 46: 33-8. PMID 19100366 DOI: 10.1053/j.seminhematol.2008.09.010  1
2009 Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, Zwaan CM, Kung AL, Armstrong SA. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 113: 2375-85. PMID 19056693 DOI: 10.1182/blood-2007-09-113597  1
2008 Jones RJ, Armstrong SA. Cancer Stem Cells in Hematopoietic Malignancies. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 14: 12-16. PMID 19122742 DOI: 10.1016/j.bbmt.2007.10.012  1
2008 Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 14: 355-68. PMID 18977325 DOI: 10.1016/j.ccr.2008.10.001  1
2008 Faber J, Gregory RI, Armstrong SA. Linking miRNA regulation to BCR-ABL expression: the next dimension. Cancer Cell. 13: 467-9. PMID 18538729 DOI: 10.1016/j.ccr.2008.05.013  1
2008 Wang Y, Armstrong SA. Cancer: inappropriate expression of stem cell programs? Cell Stem Cell. 2: 297-9. PMID 18397746 DOI: 10.1016/j.stem.2008.03.014  1
2008 Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 111: 2300-9. PMID 18056841 DOI: 10.1182/blood-2007-06-098012  1
2008 Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia. 22: 66-77. PMID 17851551 DOI: 10.1038/sj.leu.2404951  1
2007 Faber J, Armstrong SA. Defining leukemia stem cells in MLL-translocated leukemias: implications for novel therapeutic strategies. Klinische PäDiatrie. 219: 306-11. PMID 18050039 DOI: 10.1055/s-2007-985878  1
2007 Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development Nature Reviews Cancer. 7: 823-833. PMID 17957188 DOI: 10.1038/nrc2253  1
2007 Faber J, Armstrong SA. Mixed lineage leukemia translocations and a leukemia stem cell program. Cancer Research. 67: 8425-8. PMID 17875678 DOI: 10.1158/0008-5472.CAN-07-0972  1
2007 Stubbs MC, Armstrong SA. FLT3 as a therapeutic target in childhood acute leukemia Current Drug Targets. 8: 703-714. PMID 17584026 DOI: 10.2174/138945007780830782  1
2007 Stubbs MC, Armstrong SA. Therapeutic implications of leukemia stem cell development Clinical Cancer Research. 13: 3439-3442. PMID 17575205 DOI: 10.1158/1078-0432.CCR-06-3090  1
2007 Wang Y, Armstrong SA. Genome-Wide SNP Analysis in Cancer: Leukemia Shows the Way Cancer Cell. 11: 308-309. PMID 17418407 DOI: 10.1016/j.ccr.2007.03.017  1
2007 Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, ... ... Armstrong SA, et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39: 347-51. PMID 17293865 DOI: 10.1038/ng1975  1
2007 Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegué E, DePinho RA, Gilliland DG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 128: 325-39. PMID 17254970 DOI: 10.1016/j.cell.2007.01.003  1
2007 Tissing WJE, Den Boer ML, Meijerink JPP, Menezes RX, Swagemakers S, Van Der Spek PJ, Sallan SE, Armstrong SA, Pieters R. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells Blood. 109: 3929-3935. PMID 17218380 DOI: 10.1182/blood-2006-11-056366  1
2006 Sears C, Armstrong SA. Microarrays to Identify New Therapeutic Strategies for Cancer Advances in Cancer Research. 96: 51-74. PMID 17161676 DOI: 10.1016/S0065-230X(06)96003-5  1
2006 Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR, Armstrong SA. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 10: 331-42. PMID 17010674 DOI: 10.1016/j.ccr.2006.09.006  1
2006 Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (New York, N.Y.). 313: 1929-35. PMID 17008526 DOI: 10.1126/science.1132939  1
2006 Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 442: 818-22. PMID 16862118 DOI: 10.1038/nature04980  1
2006 Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 9: 351-65. PMID 16697956 DOI: 10.1016/j.ccr.2006.03.027  1
2005 Maia S, Haining WN, Ansén S, Xia Z, Armstrong SA, Seth NP, Ghia P, den Boer ML, Pieters R, Sallan SE, Nadler LM, Cardoso AA. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Research. 65: 10050-8. PMID 16267031 DOI: 10.1158/0008-5472.CAN-05-1574  1
2005 Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia Journal of Clinical Oncology. 23: 6306-6315. PMID 16155013 DOI: 10.1200/JCO.2005.05.047  1
2005 Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P, Anastasiadou E, Kutok JL, Kogan SC, Zinkel SS, Fisher JK, Hess JL, Golub TR, Armstrong SA, Akashi K, et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. The Embo Journal. 24: 368-81. PMID 15635450 DOI: 10.1038/sj.emboj.7600521  1
2004 Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, Sallan SE, Korsmeyer SJ. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 103: 3544-6. PMID 14670924 DOI: 10.1182/blood-2003-07-2441  1
2003 Armstrong SA, Golub TR, Korsmeyer SJ. MLL-rearranged leukemias: insights from gene expression profiling. Seminars in Hematology. 40: 268-73. PMID 14582077 DOI: 10.1016/S0037-1963(03)00196-3  1
2003 Armstrong SA, Korsmeyer SJ. Comparison of human genomics and genetic models of cancer to identify novel therapeutic targets Cell Cycle (Georgetown, Tex.). 2: 408-409. PMID 12963826  1
2003 Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, Korsmeyer SJ. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 3: 173-83. PMID 12620411 DOI: 10.1016/S1535-6108(03)00003-5  1
2002 Armstrong SA, Hsieh JJ, Korsmeyer SJ. Genomic approaches to the pathogenesis and treatment of acute lymphoblastic leukemias. Current Opinion in Hematology. 9: 339-44. PMID 12042709 DOI: 10.1097/00062752-200207000-00012  1
2001 Dal Cin P, Atkins L, Ford C, Ariyanayagam S, Armstrong SA, George R, Cleary A, Morton CC. Amplification of AML1 in childhood acute lymphoblastic leukemias. Genes, Chromosomes & Cancer. 30: 407-9. PMID 11241794 DOI: 10.1002/1098-2264(2001)9999:9999<::AID-GCC1107>3.0.CO;2-C  1
1995 Armstrong SA, Brown MS, Goldstein JL, Seabra MC. Preparation of recombinant Rab geranylgeranyltransferase and Rab escort proteins Methods in Enzymology. 257: 30-41. PMID 8583933 DOI: 10.1016/S0076-6879(95)57007-1  1
1995 Armstrong SA, Hannah VC, Goldstein JL, Brown MS. CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB Journal of Biological Chemistry. 270: 7864-7868. PMID 7713879 DOI: 10.1074/jbc.270.14.7864  1
1994 Cremers FPM, Armstrong SA, Seabra MC, Brown MS, Goldstein JL. REP-2, a Rab escort protein encoded by the choroideremia-like gene Journal of Biological Chemistry. 269: 2111-2117. PMID 8294464  1
1993 Andres DA, Seabra MC, Brown MS, Armstrong SA, Smeland TE, Cremers FPM, Goldstein JL. cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein Cell. 73: 1091-1099. PMID 8513495 DOI: 10.1016/0092-8674(93)90639-8  1
1993 Armstrong SA, Seabra MC, Südhof TC, Goldstein JL, Brown MS. cDNA cloning and expression of the alpha and beta subunits of rat Rab geranylgeranyl transferase. The Journal of Biological Chemistry. 268: 12221-9. PMID 8505342  1
1991 Reiss Y, Seabra MC, Armstrong SA, Slaughter CA, Goldstein JL, Brown MS. Nonidentical subunits of p21H-ras farnesyltransferase: Peptide binding and farnesyl pyrophosphate carrier functions Journal of Biological Chemistry. 266: 10672-10677. PMID 2037606  1
Show low-probability matches.